{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,9]],"date-time":"2026-01-09T21:43:11Z","timestamp":1767994991319,"version":"3.49.0"},"reference-count":22,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2015,6,1]],"date-time":"2015-06-01T00:00:00Z","timestamp":1433116800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Acta Pharmacol Sin"],"published-print":{"date-parts":[[2015,9]]},"DOI":"10.1038\/aps.2015.19","type":"journal-article","created":{"date-parts":[[2015,6,1]],"date-time":"2015-06-01T09:03:33Z","timestamp":1433149413000},"page":"1107-1112","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["LKB1 gene inactivation does not sensitize non-small cell lung cancer cells to mTOR inhibitors in vitro"],"prefix":"10.1038","volume":"36","author":[{"given":"Ping","family":"Xiao","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lin-lin","family":"Sun","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jing","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rui-li","family":"Han","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Qing","family":"Ma","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dian-sheng","family":"Zhong","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2015,6,1]]},"reference":[{"key":"BFaps201519_CR1","doi-asserted-by":"publisher","first-page":"10","DOI":"10.3322\/caac.20138","volume":"62","author":"R Siegel","year":"2012","unstructured":"Siegel R, Naishadham D, Jemal A . Cancer statistics, 2012. CA Cancer J Clin 2012; 62: 10\u201329.","journal-title":"CA Cancer J Clin"},{"key":"BFaps201519_CR2","doi-asserted-by":"publisher","first-page":"944","DOI":"10.1016\/j.febslet.2010.12.034","volume":"585","author":"K Vaahtomeri","year":"2011","unstructured":"Vaahtomeri K, M\u00e4kel\u00e4 TP . Molecular mechanisms of tumor suppression by LKB1. FEBS Lett 2011; 585: 944\u201351.","journal-title":"FEBS Lett"},{"key":"BFaps201519_CR3","doi-asserted-by":"publisher","first-page":"3562","DOI":"10.1158\/0008-5472.CAN-07-6620","volume":"6810","author":"U Shah","year":"2008","unstructured":"Shah U, Sharpless NE, Hayes DN . LKB1 and lung cancer: more than the usual suspects. Cancer Res 2008; 6810: 3562\u20135.","journal-title":"Cancer Res"},{"key":"BFaps201519_CR4","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.canlet.2011.01.014","volume":"306","author":"JL Herrmann","year":"2011","unstructured":"Herrmann JL, Byekova Y, Elmets CA, Athar M . Liver Kinase B1 (LKB1) in the pathogenesis of epithelial cancers. Cancer Lett 2011; 306: 1\u20139.","journal-title":"Cancer Lett"},{"key":"BFaps201519_CR5","doi-asserted-by":"publisher","first-page":"577","DOI":"10.1016\/S0092-8674(03)00929-2","volume":"115","author":"K Inoki","year":"2003","unstructured":"Inoki K, Zhu T, Guan KL . TSC2 mediates cellular energy response to control cell growth and survival. Cell 2003; 115: 577\u201390.","journal-title":"Cell"},{"key":"BFaps201519_CR6","doi-asserted-by":"publisher","first-page":"569","DOI":"10.1016\/j.cell.2005.10.024","volume":"123","author":"MK Holz","year":"2005","unstructured":"Holz MK, Ballif BA, Gygi SP, Blenis J . mTOR and S6K1 mediate assembly of the translation preinitiation complex through dynamic protein interchange and ordered phosphorylation events. Cell 2005; 123: 569\u201380.","journal-title":"Cell"},{"key":"BFaps201519_CR7","doi-asserted-by":"publisher","first-page":"2756","DOI":"10.1158\/1078-0432.CCR-07-1372","volume":"14","author":"DA Rizzieri","year":"2008","unstructured":"Rizzieri DA, Feldman E, DiPersio JF, Gabrail N, Stock W, Strair R, et al. A phase 2 clinical trial of deforolimus (AP23573, MK-8669), a novel mammalian target of rapamycin inhibitor, in patients with relapsed or refractory hematologic malignancies. Clin Cancer Res 2008; 14: 2756\u201362.","journal-title":"Clin Cancer Res"},{"key":"BFaps201519_CR8","doi-asserted-by":"publisher","first-page":"1286","DOI":"10.1158\/1078-0432.CCR-07-4719","volume":"14","author":"BI Rini","year":"2008","unstructured":"Rini BI . Temsirolimus, an inhibitor of mammalian target of rapamycin. Clin Cancer Res 2008; 14: 1286\u201390.","journal-title":"Clin Cancer Res"},{"key":"BFaps201519_CR9","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1200\/JCO.2008.18.9514","volume":"27","author":"BM Wolpin","year":"2009","unstructured":"Wolpin BM, Hezel AF, Abrams T, Blaszkowsky LS, Meyerhardt JA, Enzinger PC, et al. Oral mTOR inhibitor everolimus in patients with gemcitabine-refractory metastatic pancreatic cancer. J Clin Oncol 2009; 27: 193\u20138.","journal-title":"J Clin Oncol"},{"key":"BFaps201519_CR10","first-page":"893","volume":"24","author":"G Xu","year":"2004","unstructured":"Xu G, Zhang W, Bertram P, Zheng XF, McLeod H . Pharmacogenomic profiling of the PI3K\/PTEN-AKT-mTOR pathway in common human tumors. Int J Oncol 2004; 24: 893\u2013900.","journal-title":"Int J Oncol"},{"key":"BFaps201519_CR11","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1242\/dmm.004440","volume":"3","author":"CM Contreras","year":"2010","unstructured":"Contreras CM, Akbay EA, Gallardo TD, Haynie JM, Sharma S, Tagao O, et al. Lkb1 inactivation is sufficient to drive endometrial cancers that are aggressive yet highly responsive to mTOR inhibitor monotherapy. Dis Model Mech 2010; 3: 181\u201393.","journal-title":"Dis Model Mech"},{"key":"BFaps201519_CR12","first-page":"2028","volume":"124","author":"L Sun","year":"2011","unstructured":"Sun L, Zhong D, Wu S, Bai H, Chen Z . Establishment and gene expression profiling of LKB1 stable knockdown lung cancer cell line. Chin Med J(Engl) 2011; 124: 2028\u201332.","journal-title":"Chin Med J(Engl)"},{"key":"BFaps201519_CR13","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1016\/j.lungcan.2006.05.018","volume":"53","author":"D Zhong","year":"2006","unstructured":"Zhong D, Guo L, de Aguirre I, Liu X, Lamb N, Sun SY, et al. LKB1 mutation in large cell carcinoma of the lung. Lung Cancer 2006; 53: 285\u201394.","journal-title":"Lung Cancer"},{"key":"BFaps201519_CR14","doi-asserted-by":"publisher","first-page":"e48548","DOI":"10.1371\/journal.pone.0048548","volume":"7","author":"B Nyfeler","year":"2012","unstructured":"Nyfeler B, Chen Y, Li X, Pinzon-Ortiz M, Wang Z, Reddy A, et al. RAD001 enhances the potency of BEZ235 to inhibit mTOR signaling and tumor growth. PLoS one 2012; 7: e48548.","journal-title":"PLoS one"},{"key":"BFaps201519_CR15","doi-asserted-by":"publisher","first-page":"5094","DOI":"10.1002\/cncr.26165","volume":"117","author":"AX Zhu","year":"2011","unstructured":"Zhu AX, Abrams TA, Miksad R, Blaszkowsky LS, Meyerhardt JA, Zheng H, et al. Phase 1\/2 study of everolimus in advanced hepatocellular carcinoma. Cancer 2011; 117: 5094\u2013102.","journal-title":"Cancer"},{"key":"BFaps201519_CR16","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1007\/s10147-007-0733-3","volume":"13","author":"M Rizell","year":"2008","unstructured":"Rizell M, Andersson M, Cahlin C, Hafstrom L, Olausson M, Lindner P . Effects of the mTOR inhibitor sirolimus in patients with hepatocellular and cholangiocellular cancer. Int Clin Oncol 2008; 13: 66\u201370.","journal-title":"Int Clin Oncol"},{"key":"BFaps201519_CR17","doi-asserted-by":"publisher","first-page":"2278","DOI":"10.1200\/JCO.2008.20.0766","volume":"27","author":"F Meric-Bernstam","year":"2009","unstructured":"Meric-Bernstam F, Gonzalez-Angulo AM . Targeting the mTOR signaling network for cancer therapy. J Clin Oncol 2009; 27: 2278\u201387.","journal-title":"J Clin Oncol"},{"key":"BFaps201519_CR18","doi-asserted-by":"publisher","first-page":"563","DOI":"10.1038\/nrc2676","volume":"9","author":"DB Shackelford","year":"2009","unstructured":"Shackelford DB, Shaw RJ . The LKB1-AMPK pathway: metabolism and growth control in tumour suppression. Nat Rev Cancer 2009; 9: 563\u201375.","journal-title":"Nat Rev Cancer"},{"key":"BFaps201519_CR19","doi-asserted-by":"publisher","first-page":"1500","DOI":"10.1158\/0008-5472.CAN-05-2925","volume":"66","author":"KE O'Reilly","year":"2006","unstructured":"O'Reilly KE, Rojo F, She QB, Solit D, Mills GB, Smith D, et al. mTOR inhibition induces upstream receptor tyrosine kinase signaling and activates Akt. Cancer Res 2006; 66: 1500\u20138.","journal-title":"Cancer Res"},{"key":"BFaps201519_CR20","doi-asserted-by":"publisher","first-page":"7052","DOI":"10.1158\/0008-5472.CAN-05-0917","volume":"65","author":"SY Sun","year":"2005","unstructured":"Sun SY, Rosenberg LM, Wang X, Zhou Z, Yue P, Fu H, et al. Activation of Akt and eIF4E survival pathways by rapamycin-mediated mammalian target of rapamycin inhibition. Cancer Res 2005; 65: 7052\u20138.","journal-title":"Cancer Res"},{"key":"BFaps201519_CR21","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1016\/j.ccr.2010.10.031","volume":"19","author":"S Chandarlapaty","year":"2011","unstructured":"Chandarlapaty S, Sawai A, Scaltriti M, Rodrik-Outmezquine V, Grbovic-Huezo O, Serra V, et al. AKT inhibition relieves feedback suppression of receptor tyrosine kinase expression and activity. Cancer cell 2011; 19: 58\u201371.","journal-title":"Cancer cell"},{"key":"BFaps201519_CR22","doi-asserted-by":"publisher","first-page":"248","DOI":"10.1158\/2159-8290.CD-11-0085","volume":"1","author":"VS Rodrik-Outmezguine","year":"2011","unstructured":"Rodrik-Outmezguine VS, Chandarlapaty S, Pagano NC, Poulikakos PI, Scaltriti M, Moskatel E, et al. mTOR kinase inhibition causes feedback-dependent biphasic regulation of AKT signaling. Cancer Discov 2011; 1: 248\u201359.","journal-title":"Cancer Discov"}],"container-title":["Acta Pharmacologica Sinica"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.nature.com\/articles\/aps201519.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/aps201519","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/aps201519.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,18]],"date-time":"2023-05-18T12:33:01Z","timestamp":1684413181000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/aps201519"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,6,1]]},"references-count":22,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2015,9]]}},"alternative-id":["BFaps201519"],"URL":"https:\/\/doi.org\/10.1038\/aps.2015.19","relation":{},"ISSN":["1671-4083","1745-7254"],"issn-type":[{"value":"1671-4083","type":"print"},{"value":"1745-7254","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,6,1]]},"assertion":[{"value":"5 November 2014","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 March 2015","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 June 2015","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}]}}